Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103270 · ClinicalTrials.gov registry record · Phase 2
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT02103270: Completed Phase 2 study, sponsored by Stanford University.
NCT02103270 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02103270, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: * Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals. * Determine whether immune monitoring measurements reflecting underlying mechanisms during OIT can be used to predict responses to OIT in individual subjects and, ultimately, to improve the safety and efficacy outcomes in peanut OIT protocols.
Interventions
- DRUG Oat Flour
- DRUG Peanut Protein 4,000mg
- DRUG Peanut Protein 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02103270
The ClinicalTrials.gov registry entry for NCT02103270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oat Flour is the first listed.
NCT02103270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02103270 about?
NCT02103270 is a clinical study titled "The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery". Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: * Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals. * Deter...
What is the current status of trial NCT02103270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2018-09-01.
What interventions are being tested in trial NCT02103270?
The interventions under investigation include: Oat Flour (DRUG), Peanut Protein 4,000mg (DRUG), Peanut Protein 300 mg (DRUG).
Who is sponsoring clinical trial NCT02103270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.